Veeva Posts A Solid Q2 Report

Recently re-instated watch list stock Veeva Systems reported its Q2 this week. Sales were up 15%, and profitability rose significantly. This steady and predictable provider of clinical and business software for life sciences firm has a very wide moat and is methodically expanding its product suite into new areas. I love the company but the stock is rarely inexpensive enough to buy. The fair value is $188. After earnings, the stock is trading a good bit above that. We'll leave it on watch.

Watch List

APPF -3.02%
CMG 43.83%
VEEV 16.09%
INTU 19.56%
WDAY -7.52%
PSTG -0.65%
RDDT 18.10%
NTNX 24.37%
CRWD 94.01%
SE 26.50%
SNOW 13.14%

Buy List

PINS -36.44%
SEMR -33.35%
TSM -40.82%
ZETA -27.00%
GOOG -49.43%
NYAX -28.98%
MSFT -28.62%
ODD -29.76%
FLYW -42.32%
HRMY -59.44%
YOU -38.27%
ABNB -31.17%
ADBE -42.81%

Hold List

ASML -22.86%
VTEX -14.24%
ASR -23.26%
CELH 46.96%
TOST 20.33%
CPNG -11.55%
HIMS -19.74%
PAYC -18.13%
MNDY 18.61%
GLBE -21.26%
ZS 32.26%
V -7.16%
ADSK -0.03%
NOW 14.16%
MELI -23.30%
FTNT -0.20%
TEAM 0.30%